



20 November 2023

Sydney, Australia

## Nyrada Annual General Meeting Results

---

**Nyrada Inc (ASX:NYR)**, a drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, announces the results of today's Annual General Meeting.

The results are set out in the attached document, in accordance with ASX Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act.

***All resolutions were passed and decided by way of a poll.***

-ENDS-

### About Nyrada Inc

Nyrada is a drug discovery and development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.*

#### Investor & Corporate Enquiries:

Dimitri Burshtein

T: 02 9498 3390

E: [info@nyrada.com](mailto:info@nyrada.com)

#### Company Secretary:

David Franks

T: 02 8072 1400

E: [david.franks@atomicgroup.com.au](mailto:david.franks@atomicgroup.com.au)

#### Media Enquiries:

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)



## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

# Disclosure of Proxy Votes

Nyrada Inc

Annual General Meeting

Monday, 20 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Re-election of John Moore as Director	P	15,602,993	15,602,993 100.00%	0 0.00%	36,796,945	0 0.00%	17,002,993 100.00%	0 0.00%	36,796,945	Passed
2 Re-election of Christopher Cox as Director	P	14,434,772	14,434,772 100.00%	0 0.00%	37,965,166	0 0.00%	15,834,772 100.00%	0 0.00%	37,965,166	Passed
3 Re-election of Dr. Ian Dixon as Director	P	14,531,618	14,531,618 100.00%	0 0.00%	37,868,320	0 0.00%	14,531,618 100.00%	0 0.00%	39,268,320	Passed
4 Re-election of Marcus Frampton as Director	P	15,417,918	15,417,918 100.00%	0 0.00%	36,982,020	0 0.00%	16,817,918 100.00%	0 0.00%	36,982,020	Passed
5 Re-election of Dr. Rüdiger Weseloh as Director	P	15,602,993	15,602,993 100.00%	0 0.00%	36,796,945	0 0.00%	17,002,993 100.00%	0 0.00%	36,796,945	Passed
6 Re-election of Dr. Gisela Mautner as Director	P	15,602,993	15,602,993 100.00%	0 0.00%	36,796,945	0 0.00%	17,002,993 100.00%	0 0.00%	36,796,945	Passed
7 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	52,399,938	49,840,751 95.12%	2,559,187 4.88%	0	0 0.00%	51,240,751 95.24%	2,559,187 4.76%	0	Passed
8 Approval of Issue of Incentive Securities to Dr. Gisela Mautner, Director of the Company	P	40,436,407	3,462,971 8.56%	3,600,191 8.90%	0	33,373,245 82.53%	38,236,216 91.39%	3,600,191 8.61%	0	Passed



			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
9 Amendment to the Company's Certificate of Incorporation	P	52,399,938	16,424,772 31.35%	2,601,921 4.97%	0	33,373,245 63.69%	51,198,017 95.16%	2,601,921 4.84%	0	Passed

